Gyre Therapeutics reported a mixed third quarter with strong revenue growth driven by ETUARY® and new product contributions, but revised full-year revenue guidance downwards due to delayed product rollouts and market uncertainties.
Quarterly revenue of $30.6 million, up 20% year-over-year, driven by ETUARY® growth and contributions from sales of Etorel® and Contiva®.
positiveGAAP net income doubled to $5.9 million and adjusted net income rose to $8.8 million, reflecting commercial execution and disciplined cost control.
positiveOperating income increased 64% to $6.9 million, as operating expenses grew at a slower pace than revenue.
positiveBasic EPS improved to $0.04, compared to $0.01 year-over-year for the quarter.
positive$80.3 million in cash, cash equivalents, and short and long-term deposits, up 57% year-to-date, as of Sept 30, 2025.
positiveFull-year revenue guidance revised to $115-118 million (from $118 - $128 million previously) due to delayed Etorel® rollout and government procurement-related uncertainty.
negativeNine-month revenue of $79.4 million, only moderately above the prior-year period, impacted by earlier supply chain and distribution delays.
attentionBasic EPS down from $0.14 to $0.08 for the nine months ended September 30, 2025, reflecting higher operating expenses related to dual product launches.
negativeU.S. MASH IND anticipated timeline adjusted to 2026, delaying potential market entry.
attentionMargin metrics will be available once backend extracts data from insights_json
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Following the positive results from our pivotal Phase 3 trial in the PRC evaluating Hydronidone for the treatment of CHB-associated liver fibrosis, we are working diligently toward our NDA submission and are leveraging Hydronidone’s Breakthrough Therapy designation to bring this much-needed therapy to patients in China.
With enrollment now completed in our 52-week Phase 3 trial of pirfenidone for the treatment of pneumoconiosis, we continue to advance our pipeline in China.
We are also preparing for U.S. clinical activities and expect to file the U.S. IND for Hydronidone for the treatment of MASH-associated liver fibrosis in 2026, supported by the translation and regulatory-quality review of our China Phase 2 and Phase 3 trial data and an upcoming hepatic impairment study.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.